TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01770821

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary supplement and/or physical training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary supplement and/or physical training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary supplement and/or physical training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary supplement and/or physical training
Study: NCT01324921

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No breakfast/beverage only
Description: 12 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast
Description: 1 serving of unflavored instant oatmeal and 12 fluid ounces made up of one of some combination of the following:decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10004RF
Description: 1 serving (8 fluid ounces) of the experimental beverage and 4 fluid ounces made up of one of some combination of the following:decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
Study: NCT02566499

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breast Microwave Imaging
Description: A Breast Microwave Imaging Procedure will be carried out on volunteers who have abnormal x-ray mammograms, prior to the volunteer undergoing a biopsy to confirm diagnosis (as part of their normal care).
Study: NCT00698685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Days - 8 through -6: pentostatin 4 mg/m2/24 hr as a continuous intravenous infusion (CIVI) (total cumulative dose, 12 mg/m2 over 3 days)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Days - 5 through - 1: alemtuzumab 20 mg per dose intravenously over 8 hours daily for 5 doses (total cumulative dose, 100 mg)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation
Description: Infusion of related or unrelated donor peripheral blood progenitor cells on day 0.
Study: NCT01197313

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based exercise
Study: NCT03441100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMADetect®
Description: IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in clinical trials. IMADetect® is intended for investigational use only.
Study: NCT02784106

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo matched to M2951 twice daily up to Day 84 during the double-blind treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2951
Description: Participants received 50 milligrams (mg) M2951 orally twice daily up to Day 84 during the double-blind treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2951
Description: Participants who received placebo matched to M2951 or M2951 in double-blind treatment period, received 50 mg M2951 orally twice daily up to 26-weeks during the open label extension period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2951
Description: Participants who received placebo matched to M2951 or M2951 in double-blind treatment period, received 50 mg M2951 orally twice daily up to 26-weeks during the open label extension period.
Study: NCT00203879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAGE-3/Melan-A/gp100/NA PBMC, rhIL-12 (drug)
Description: draft

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2
Description: MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2
Study: NCT00390312

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Placebo
Description: Intranasal placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Morphine 15 mg
Description: Intranasal Morphine 15 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Release Oral Morphine 60 mg
Description: Immediate Release Oral Morphine 60 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous morphine
Description: Intravenous morphine 7.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal morphine 7.5 mg
Description: Intranasal morphine 7.5 mg
Study: NCT04918004

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene
Description: 1. One-to-one sleep hygiene training, the content of which was created by the researchers,~2. A brochure containing 10 lifestyle changes related to sleep hygiene
Study: NCT04043897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin 550mg
Description: Rifaximin 550mg
Study: NCT00452907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: oad, per os, 3 days of treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate + Sulfadoxine-Pyrimethamine
Description: oad, per os

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arthemether + lumefantrine
Description: bid, per os. Duration of treatment: 3 days
Study: NCT02110004

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ablation procedure
Description: The primary purpose of the First-In-Man clinical investigation is to assess the Picasso NAV Catheter's ability to collect intra-cardiac signals within the desired chambers (atrial and/or ventricle) in the heart for the analysis of complex arrhythmias.

Intervention type: DEVICE
Group type: OTHER
Intervention: Picasso NAV Catheter
Study: NCT02594787

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Phosphorus

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05101512

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires on quality of life after surgery
Description: Patient has to answer different questionnaire about quality of life, pain, functional scores
Study: NCT01739257

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical Lecture

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dramatic Reading
Study: NCT03820297

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 10 sessions of ASGI
Description: 10-session intervention will occur weekly for 45 minutes per session: psychoeducation about mood and anxiety disorders, focusing on identification of risk factors and biological theory to counter stigma; psychoeducation regarding 'therapeutic modules' (psychotropics and psychotherapy) to treat depression, with an emphasis on the importance of psychiatric treatment adherence, providing behavioral strategies for anticipated and experienced forms of mental illness related work, social, or family discrimination
Study: NCT01546246

Intervention type: OTHER
Group type: OTHER
Intervention: Water colonoscopy
Description: Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
Study: NCT01300442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEDS in COPD patients
Description: For the TEDS (transcutaneous electrical diaphragmatic stimulation) the electrical current is pulsed, biphasic and symmetric, with the following parameters: frequency of 30 Hertz; 0.4ms phase width, rise time of 0.7 seconds; respiratory rate of 14 rpm; intensity is the minimum necessary to obtain diaphragm muscle contraction. Four silicone-carbon electrodes (3x5cm) were placed on the skin with gel and micropore tape. Two electrodes were located on each side of the thorax, specifically in the 3rd intercostal space near the xyphoid region and in the 7th intercostal space, on the mid-axillary line. Each session had duration of approximately 30 minutes and the subjects were instructed to co-ordinate breathing with the pulsing of the electrical current.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEDS in healthy patients
Description: For the TEDS (transcutaneous electrical diaphragmatic stimulation) the electrical current is pulsed, biphasic and symmetric, with the following parameters: frequency of 30 Hertz; 0.4ms phase width, rise time of 0.7 seconds; respiratory rate of 14 rpm; intensity is the minimum necessary to obtain diaphragm muscle contraction. Four silicone-carbon electrodes (3x5cm) were placed on the skin with gel and micropore tape. Two electrodes were located on each side of the thorax, specifically in the 3rd intercostal space near the xyphoid region and in the 7th intercostal space, on the mid-axillary line. Each session had duration of approximately 30 minutes and the subjects were instructed to co-ordinate breathing with the pulsing of the electrical current.
Study: NCT00506805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNX-5422
Description: dose escalated, tablets every other day; undetermined duration until disease progression
Study: NCT03242512

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TK006
Description: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TK006
Description: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TK006
Description: Subcutaneous injection
Study: NCT00504075

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gammaplex, intravenous immunoglobulin
Description: Dosage form: Gammaplex® is a sterile liquid of 5 % w/v normal immunoglobulin. Gammaplex® contains 5 g/100 mL of human normal immunoglobulin (i.e. 50 g/L, of which virtually 100% is IgG).~The first course of GAMMAPLEX will be administered as an intravenous infusion of 1 g/kg on each of 2 consecutive days. If required, a further 1 or 2 courses on the same dosage regimen may be administered in the period Day 32 to Day 90 following the first course of GAMMAPLEX.
Study: NCT01124968

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eConsulta
Description: It is a web specifically designed for the project where elected patients can consult virtually with their primary care physician and within 48 hours have an answer.
Study: NCT04517708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional counseling
Description: Each patient was assigned a specific menu which were prepared by research members during the time of staying at the hospital. Before discharge, patients were instructed on preparing their diets at home with the recommended amount of energy and protein and given formula milk within two months
Study: NCT01821768

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sentinel Lymph Node Biopsy
Study: NCT03993808

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Revision of congregate meal menus and recipes to align with parameters of DASH eating plan
Description: On a programmatic level, congregate meal menus and recipes have been adapted to align with DASH eating. The changes, which include the introduction of additional servings of fruits, vegetables, seeds, grains, replacement of simple or processed carbohydrates with healthier alternatives, introduction of more fish, reduction in added salt, and replacement of animal fats and butter with olive oil, will be phased-in in stages over 6 weeks, concurrent with the start up the study's educational programs addressing nutrition, BP, and medication adherence. The fully DASH-aligned menus will begin by week 7. The dietary intervention affects all seniors eating congregate meals at the center, not only those enrolled in this protocol to study the impact of DASH implementation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On-site blood pressure monitoring
Description: At baseline (Month 0), and at Months 1, 3, and 6 after the full implementation of the DASH aligned congregate meals, participants will have blood pressure measured by professionals, on-site at the senior center, following established standard procedures. They will receive verbal and written information about their blood pressure results, and encouragement to share the results with their providers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home self blood pressure monitoring
Description: Provision of personal Omron 10 home blood pressure monitoring device, training in proper use, and schedule for home self monitoring of BP over the course of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical adherence education
Description: One required educational session with the community pharmacist to learn about medication adherence strategies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education
Description: One required educational session to review the elements of the DASH eating plan, how to overcome barriers to healthy eating, recipes, cooking demonstrations and materials for household members.
Study: NCT02328079

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids (Prednisolone) and Steroids plus Antiviral (Prednisolone + acyclovir)
Description: Group allocations: Steroid group (prednisolone 60 mg /day IM /IV), Steroid plus Antiviral group (Prednisolone IM/ IV 60 mg /day + IV acyclovir 500 mg three time /day for 6 consecutive days) then reduced by 10 mg /day (for a total treatment time for 12 days) were placed in serially-numbered opaque closed envelopes. Each patient was placed in the appropriate group after opening the corresponding sealed envelope.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids (Prednisolone) and Steroids plus Antiviral (Prednisolone + acyclovir)
Description: Group allocations: Steroid group (prednisolone 60 mg /day IM /IV), Steroid plus Antiviral group (Prednisolone IM/ IV 60 mg /day + IV acyclovir 500 mg three time /day for 6 consecutive days) then reduced by 10 mg /day (for a total treatment time for 12 days) were placed in serially-numbered opaque closed envelopes. Each patient was placed in the appropriate group after opening the corresponding sealed envelope.
Study: NCT03496077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavored and unflavored little cigars/cigarillos (LCCs)
Description: Flavored and unflavored LCCs that are currently available for purchase

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavored and unflavored little cigars/cigarillos (LCCs)
Description: Flavored and unflavored LCCs that are currently available for purchase
Study: NCT03728270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient Specific Titanium Eminoplasty
Description: * The stages of virtual surgical planning and fabrication of patient specific titanium eminoplasty will be designed my Mimics 15 program.~* Once designed, the virtual design and surgery will be planned on a computer model where vital anatomical structures could be identified and thus could be avoided during surgery.~* After obtaining all the dataset needed from the CT scan, the collected data will be sent to the Egyptian soil, water and environmental institution for manufacturing, packing and sterilization of the patient specific titanium eminence.~* The patient specific titanium eminence will be inserted and secured with two to three screws of individual lengths according to the virtual plan.~* Functional mandibular movements were reproduced to confirm absence of subluxation and checked for interference and any required adjustments made.~* A multilayer closure of the incisions will be accomplished using Vicryl

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inlay Autogenous Bone Graft
Description: \* Steps to harvest the bone graft:~* Down-fracture of the articular eminence to be augmented with Inlay bone graft to increase the vertical height of the articular eminence. A green-stick fracture will be created avoiding a possible complete fracture of the lower segment of the eminence~* To obtain Inlay bone graft from the chin, anterior mandibular vestibule incision will provide good access to the mandibular symphysis.
Study: NCT02931253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be started as one pill (500 mg metformin) once a day with a meal. If the subject has no side effects from this dose, the dose will be increased to two pills (1000 mg) twice a day to be taken with meals.
Study: NCT04256863

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breakfast / Lunch
Description: Participants in the BFL group will participate in 16 weekly, group based sessions weekly sessions in which they will be exposed to standard behavioral therapy (SBT) for weight control. Each 90-minute session will cover one weight control topic (self-monitoring, modifying the home food environment, physical activity, goal setting, stimulus control, stress-related eating, motivation, problem solving, healthy eating on a budget, social influences and weight loss maintenance) and an experiential learning activity. These hands-on activities will help teens build skills to adhere to 1) their calorie goal (1,400 - 1,600 calories/day) and 2) the prescribed timing for consumption (\>50% of their energy needs consumed before 3PM every day of the week. Sample meal plans will be provided to help with adherence. .

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dinner (DIN)
Description: Participants randomized to the Dinner (DIN) group will participate in the same 16-week intervention as those in the BFL group; however, the topics covered in the experiential learning session will pertain to skills needed to adhere to prescribed calorie goals NOT to timing. They will be instructed to consume \>50% of their energy needs after 3PM daily.; however, given that most teens consume the bulk of their calories after 5PM, the focus will be on general calorie goals vs. timing., Teens in this group will also be provided sample meal plans that outline how to spread out their calorie intake across breakfast (200), lunch (300), after school snack (200 calories), Dinner (700 calories), after dinner snack (200 calories for 1,600 calorie diet only).
Study: NCT01048697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: All volunteers in each category will receive a single dose of oral ethambutol based on American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of American (ATS/CDC/IDSA) TB treatment guidelines.1 We will not use any doses higher than the maximum dose recommended for daily administration by the current ATS/CDC/IDSA TB guidelines (which use ideal body weight for dosing):~40-55kg: 800 mg (two 400 mg tablets) 56-75kg: 1,200 mg (three 400 mg tablets) 76-90kg: 1,600 mg (four 400 mg tablets) \> 90 kg: No dosage recommendations so these volunteers will only receive 1,600 mg (four 400 mg tablets)
Study: NCT02506751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liothyronine
Description: All eligible subjects will be treated with the study drug as per the standardized dose-escalation protocol. Subjects will be required to report to the study site every six weeks for the duration of the study in order to receive their study drug and to monitor drug safety and tolerability.
Study: NCT01133223

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Penumbra™ System
Description: Patients assigned to the Thrombectomy arm will be conducted to the angio suite. Mechanical thrombectomy will be attempted with the use of the Penumbra™ System, and can be assisted by intraarterial thrombolysis (rTPA up to 20 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant tissue plasminogen activator
Description: Patients assigned to Usual Care arm will be thrombolysed according to the NINDS protocol (rtPA 0,9 mg/kg, 10% IV bolus and remaining in the next hour, up to 90 mg)
Study: NCT02952196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drug administration
Description: administering drug to patient with amphetamine addiction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drug administration
Description: administering drug to patient with amphetamine addiction

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: drug administration
Description: administering drug to patient with amphetamine addiction
Study: NCT03019081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoproterenol
Description: The goal of this experiment is to use isoproterenol in the context of inhibitory fear learning to reduce eating-related anxiety in AN, and to explore whether these changes are related to interoceptive awareness and autonomic reactivity.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02167919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microspheres
Description: Prostatic artery embolization (PAE) is a new procedure that decreases the size of the prostate by blocking its arterial blood flow. Through a tiny puncture in the upper thigh or forearm a catheter is directed to the prostatic artery using fluoroscopic guidance. Once in place, sub-millimeter particles are injected that obstruct the prostatic arteries resulting in gland ischemia, and ultimately, reduction in size. The technique has only been recently developed in Portugal and Brazil and has similarities to Uterine Artery Embolization used to treat uterine fibroids.
Study: NCT03177239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Dosage Form: Nivolumab BMS-936558-01 Solution for Injection Potency: 100 mg (10 mg/mL) Primary Packaging: 10 mL vial Appearance: Clear to opalescent colourless to pale yellow liquid. May contain particles.~Storage Condition: 2 to 8°C. Protect from light and freezing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Dosage Form: Ipilimumab Solution for Injection Potency: 200 mg (5 mg/mL) Primary Packaging: 40 mL vial Appearance: Clear, colourless to pale yellow liquid. May contain particles. Storage Condition: 2 to 8°C. Protect from light and freezing.